CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 419 enrolled
Drug / intervention
ABT-450/r/ABT-267, ABT-333 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01767116
NCT01767116Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)

AbbVie (prior sponsor, Abbott)·interventional·Posted Jan 14, 2013·Updated Jul 12, 2021

In Brief

A Phase 3 clinical trial evaluating ABT-450/r/ABT-267, ABT-333, Ribavirin, and 1 other intervention for Chronic Hepatitis C Infection. Completed, enrolled 419 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2013
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.5 years ago

Interventions

ABT-450/r/ABT-267, ABT-333drug

Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Ribavirindrug

Capsule

Placebo for ribavirindrug

Capsule